Premium
Metronidazole containing pyrazole derivatives potently inhibit tyrosyl‐tRNA synthetase: design, synthesis, and biological evaluation
Author(s) -
Chen LongWang,
Wang PengFei,
Tang DanJie,
Tao XiangXiang,
Man RuoJun,
Qiu HanYue,
Wang ZhongChang,
Xu Chen,
Zhu HaiLiang
Publication year - 2016
Publication title -
chemical biology and drug design
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 77
eISSN - 1747-0285
pISSN - 1747-0277
DOI - 10.1111/cbdd.12793
Subject(s) - antibacterial activity , cytotoxicity , docking (animal) , enzyme , chemistry , biochemistry , flow cytometry , potency , pyrazole , minimum inhibitory concentration , in vitro , stereochemistry , bacteria , biology , microbiology and biotechnology , medicine , genetics , nursing
As an important enzyme in bacterial protein biosynthesis, tyrosyl‐t RNA synthetase ( T yr RS ) has been an absorbing therapeutic target for exploring novel antibacterial agents. A series of metronidazole‐based antibacterial agents has been synthesized and identified as T yr RS inhibitors with low cytotoxicity and significant antibacterial activity, especially against Gram‐negative organisms. Of the compounds obtained, 4f is the most potent agent which inhibited the growth of P seudomonas aeruginosa ATCC 13525 ( MIC = 0.98 μ g/mL) and exhibited T ry RS inhibitory activity ( IC 50 = 0.92 μ m ). Docking simulation was performed to further understand its potency. Membrane‐mediated apoptosis in P . aeruginosa was verified by flow cytometry.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom